Specify a stock or a cryptocurrency in the search bar to get a summary
Orthocell Ltd
OCCOrthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia, the United States, the United Kingdom, and the European Union. The company offers Ortho-ATI, a cell therapy for treatment of chronic tendon injuries; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; Remplir, a collagen scaffold used in peripheral nerve repair; and Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia. Address: Building 191, Murdoch, WA, Australia, 6150
Analytics
WallStreet Target Price
0.85 AUDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures OCC
Dividend Analytics OCC
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History OCC
Stock Valuation OCC
Financials OCC
Results | 2019 | Dynamics |